Acadia Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACADIA Pharmaceuticals NASDAQ: ACAD executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference.
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.11 per share a year ago.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Bank of America upgraded Acadia Pharmaceuticals (NASDAQ:ACAD) to 'Buy' from 'Neutral', arguing that a recent pullback in the stock has created a more attractive risk-reward profile for investors. The analysts maintained a $29 price objective on the shares, which traded up 6% at $22 on Wednesday afternoon, and wrote that the roughly 25% decline in the stock is “not related to fundamentals and more related to YTD macro factors.
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
First Trust Advisors LP lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 20.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,943,152 shares of the biopharmaceutical company's stock after selling 491,224 shares during the quarter. First Trust
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Acadia plans re-examination after CHMP rejects Rett syndrome drug trofinetide in the EU, delays potential approval despite positive LAVENDER study results.
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
